XORTX Therapeutics (XRTX) Capital Expenditures (2022 - 2023)
XORTX Therapeutics' (XRTX) quarterly Capital Expenditures came in at $8621.0 in Q4 2023, down 74.19% YoY from $33402.8 in Q4 2022, and up 626.63% on a QoQ basis from -$1637.0 in Q2 2023.
XORTX Therapeutics (XRTX) Capital Expenditures (2022 - 2023) Analysis & Trends
XORTX Therapeutics (XRTX) has 2 years of Capital Expenditures data on file, last reported at $8621.0 in Q4 2023.
- Quarterly Capital Expenditures fell 74.19% year-over-year to $8621.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $4311.0 (changed N/A YoY) and the FY2023 annual result came in at $4311.0, down 78.11% from the prior year.
- Capital Expenditures rose to $8621.0 in Q4 2023, from -$1637.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $33402.8 in Q4 2022 to a low of -$2673.0 in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | 251.02 Mn |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 8,621.00 |
| Dec 31, 2023 | 8,621.00 |
| Jun 30, 2023 | -1,637.00 |
| Jun 30, 2023 | -1,637.00 |
| Mar 31, 2023 | -2,673.00 |
| Mar 31, 2023 | -2,673.00 |
| Dec 31, 2022 | 33,402.85 |
| Dec 31, 2022 | 33,402.85 |
| Sep 30, 2022 | -444.71 |
| Sep 30, 2022 | -444.71 |